He currently serves as the senior vice president of research at Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Cambridge, MA.
Manning is responsible for research and the discovery of novel products as the senior vice president of research at Momenta Pharmaceuticals, Inc.
Since joining Momenta, his team has advanced three novel autoimmune drugs into development.
Prior to Momenta, Manning was vice president and head of immunology research for Biogen Idec, Inc.
Before that, he was vice president and global head of inflammation, autoimmunity and transplantation research at Roche Pharmaceuticals.
Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer